BusinessBiothera Pharmaceuticals Presents Translational Data from Ongoing Clinical Trials Showing Imprime PGG in Combination with Merck’s KEYTRUDA® (pembrolizumab) Drives Innate and Adaptive Immune Responses in TumorsBy Nasdaq OMXApr 16, 2018, 1:01 PM UTC
BusinessBiothera Pharmaceuticals Enters Cancer Immunotherapy Clinical Trial Collaboration AgreementBy Nasdaq OMXNov 28, 2017, 2:01 PM UTC
BusinessBiothera Pharmaceuticals Announces Presentations on Imprime PGG at Three Upcoming Healthcare ConferencesBy Nasdaq OMXSep 28, 2017, 4:09 PM UTC
